New Delhi, Oct 12: The long wait is over. Finally, one vaccine against Covid-19 gets approval for emergency use in children aged 2 – 18 years. The national drugs regulator’s subject expert committee (SEC) gave this approval. Bharat Biotech’s Covaxin successfully completed the phase 2 and 3 level clinical trials in children. Covaxin Clinical trials data of 2-18 years age group was submitted to Central Drugs Standard Control Organisation (CDSCO). Covaxin is the first Covid-19 vaccine to be tested in the 2-6 years age group. The made-in-India vaccine will be administered in two doses, with a gap of 28 days in between the first and second dose. In August, India had also granted emergency use approval to ZyCov-D’s Covid- 19 vaccine for children between the ages of 12 to 18. The vaccine is developed by pharmaceutical firm Zydus Cadila and is the first DNA vaccine to be approved in the world.
